Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) insider Douglas M. Hunt sold 3,443 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $3.54, for a total transaction of $12,188.22. Following the sale, the insider directly owned 164,894 shares of the company's stock, valued at $583,724.76. The trade was a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Puma Biotechnology Stock Performance
Shares of NASDAQ PBYI traded down $0.13 during midday trading on Friday, reaching $3.39. The company had a trading volume of 300,719 shares, compared to its average volume of 414,077. The business's 50-day simple moving average is $3.37 and its 200 day simple moving average is $3.18. The stock has a market cap of $168.25 million, a P/E ratio of 4.40 and a beta of 1.29. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $4.13. The company has a current ratio of 1.53, a quick ratio of 1.43 and a debt-to-equity ratio of 0.11.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.
Get Our Latest Research Report on PBYI
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio purchased a new position in shares of Puma Biotechnology in the first quarter worth $420,000. Acadian Asset Management LLC raised its holdings in shares of Puma Biotechnology by 1.8% in the first quarter. Acadian Asset Management LLC now owns 2,008,146 shares of the biopharmaceutical company's stock worth $5,940,000 after buying an additional 36,018 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Puma Biotechnology in the first quarter worth $66,000. AQR Capital Management LLC raised its holdings in shares of Puma Biotechnology by 366.5% in the first quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company's stock worth $149,000 after buying an additional 39,641 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Puma Biotechnology by 3.8% in the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock worth $254,000 after buying an additional 3,117 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company's stock.
About Puma Biotechnology
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
See Also
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
